Vivesto (VIVE) Q3 2025 earnings summary

Executive summary

• Strategic focus on high-potential oncology programs Paccal Vet (veterinary) and Cantrixil (hematological cancer) has yielded positive clinical and preclinical results, supporting the company's transformation and cost efficiency efforts.

• Positive interim data from Paccal Vet pilot study in dogs with hemangiosarcoma and initial dosing in cats with solid tumors; Cantrixil showed efficacy in preclinical AML models and a new international patent application was filed.

• Full global rights to Cantrixil acquired, eliminating future royalty and milestone obligations.

Financial highlights

• Net sales were SEK 0 thousand for both Q3 and the nine-month period (unchanged year-over-year).

• Operating loss for Q3 was SEK -7,136 thousand (improved from -10,812), and for the nine-month period SEK -25,463 thousand (improved from -31,007).

• Net loss after tax for Q3 was SEK -7,191 thousand (improved from -10,260), and for the nine-month period SEK -25,005 thousand (improved from -29,043).

• Cash and short-term investments at period end totaled SEK 1,462 thousand (down from 40,885).

• Cash flow for the nine-month period was SEK -229 thousand (improved from -2,858).

Outlook and guidance

• Full results from Paccal Vet studies in dogs and cats expected in 2026; key PK and toxicology studies for Cantrixil planned, with a pilot canine cancer study to be initiated.

• Active search for strategic partners to advance clinical development and commercialization of both lead programs.

• Management believes financing for the next 12 months is achievable, with ongoing evaluation of funding options.